Sodium Sulfide
CAS 1313-82-2
Sodium Sulfide (CAS 1313-82-2) is a Phase 2 pharmaceutical compound with 1 bioactivity target and 4 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | MIC | 1.95 ug.mL-1 | 1 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Sodium Sulfide used for in pharmaceutical contexts?
Sodium Sulfide (CAS 1313-82-2) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Sodium Sulfide?
Sodium Sulfide has 4 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Alanine aminotransferase increased, Aspartate aminotransferase increased, Gamma-glutamyltransferase increased, Hepatic cytolysis. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Sodium Sulfide also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Sodium Sulfide with EU status "restricted".
What clinical phase is Sodium Sulfide in?
Sodium Sulfide is rendered with ChEMBL max phase 2.